X
[{"orgOrder":0,"company":"QOL Medical","sponsor":"Optum Frontier Therapies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"QOL Medical, LLC Selects Optum Frontier Therapies as an Exclusive Pharmacy Partner to Best Support Congenital Sucrase-Isomaltase Deficiency (CSID) Patients on Sucraid\u00ae (sacrosidase) Oral Solution","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"},{"orgOrder":0,"company":"QOL Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"QOL Medical, LLC Receives FDA Approval of Sucraid\u00ae (sacrosidase) Oral Solution Single-Use Containers for Patients with Congenital Sucrase-Isomaltase Deficiency (CSID)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"}]
Find Clinical Drug Pipeline Developments & Deals by QOL Medical
Filters
Companies By Therapeutic Area
Details:
Sucraid® (sacrosidase) Oral Solution is an enzyme replacement therapy for the treatment of genetically determined sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID).
Lead Product(s):
Sacrosidase
Therapeutic Area: Genetic Disease
Product Name: Sucraid
Highest Development Status: Approved
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 06, 2022
Details:
Sucraid® (sacrosidase) Oral Solution is an enzyme replacement therapy for the treatment of genetically determined sucrase deficiency, which is part of Congenital Sucrase-Isomaltase Deficiency (CSID).
Lead Product(s):
Sacrosidase
Therapeutic Area: Genetic Disease
Product Name: Sucraid
Highest Development Status: Approved
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Optum Frontier Therapies
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Partnership
April 15, 2022